The operating expense ratio was 17.3 % and 18.3 % for the third quarters of 2013 and 2012, respectively. The improvement in the operating expense ratio is primarily driven by operating income growth and continued execution of our expense initiatives, including execution on our Coventry-related price synergies. The full total company expenditure ratio was 17.7 % and 18.4 % for the third quarters of 2013 and 2012, respectively.9 % for the 3rd quarter of 2013 compared with 10.2 % for the third quarter of 2012 credited to lower underwriting margins in our underlying Medicare business primarily.Hazard ratios for disease progression or death generally favored lanreotide more than placebo in the predefined subgroups ., and Fig. S2 and S3 in the Supplementary Appendix). The exceptions were small subgroups , that the hazard ratios had wide confidence intervals and the findings were imprecise. Additional End Points The odds ratio to be alive without centrally assessed disease progression at weeks 48 and 96 , and also the time to tumor progression, significantly favored lanreotide over placebo at each time point .). Although overall survival didn’t differ significantly between your study groups, the analysis was complicated by crossover from the placebo group to the lanreotide group and uncertainty over treatments after progression .